- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
Patent holdings for IPC class A61K 31/416
Total number of patents in this class: 2115
10-year publication summary
|
121
|
121
|
139
|
132
|
111
|
113
|
109
|
120
|
131
|
80
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10744 |
41 |
| Glaxo Group Limited | 4063 |
31 |
| Merck Sharp & Dohme LLC | 3751 |
28 |
| F. Hoffmann-La Roche AG | 7947 |
26 |
| The Regents of the University of California | 19961 |
24 |
| Merck Sharp & Dohme Corp. | 2191 |
24 |
| AstraZeneca AB | 2892 |
24 |
| Boehringer Ingelheim International GmbH | 4642 |
23 |
| Takeda Pharmaceutical Company Limited | 2708 |
22 |
| Bristol-myers Squibb Company | 4880 |
21 |
| Janssen Pharmaceutica N.V. | 3394 |
20 |
| University Health Network | 1045 |
19 |
| Genentech, Inc. | 3976 |
18 |
| Arena Pharmaceuticals, Inc. | 365 |
18 |
| Abbvie Inc. | 1800 |
17 |
| Translatum Medicus Inc. | 25 |
17 |
| Bayer Pharma AG | 1053 |
15 |
| Biosplice Therapeutics, Inc. | 171 |
15 |
| Achillion Pharmaceuticals, Inc. | 164 |
14 |
| Pfizer Inc. | 3371 |
13 |
| Other owners | 1685 |